Published in Antiviral Res on August 15, 2007
Targeting an Essential GTPase Obg for the Development of Broad-Spectrum Antibiotics. PLoS One (2016) 0.76
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J (2006) 1.69
The vaccinia virus I7L gene product is the core protein proteinase. J Virol (2002) 1.61
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol (2003) 1.20
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther (2007) 1.17
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilin. J Bacteriol (2002) 1.16
Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun (2006) 1.07
New class of orthopoxvirus antiviral drugs that block viral maturation. J Virol (2004) 1.07
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother (2009) 1.07
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo. J Virol (2004) 1.04
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J (2009) 1.03
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol (2007) 1.02
A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virol J (2005) 1.01
Conditional expression of vaccinia virus genes in mammalian cell lines expressing the tetracycline repressor. J Virol Methods (2004) 1.01
Vaccinia virus proteolysis--a review. Rev Med Virol (2006) 1.00
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
Chlamydial development is blocked in host cells transfected with Chlamydophila caviae incA. BMC Microbiol (2004) 0.94
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis (2012) 0.93
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother (2010) 0.91
Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother (2013) 0.91
Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun (2005) 0.88
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother (2013) 0.85
SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity. Bioorg Med Chem Lett (2012) 0.85
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine (2010) 0.84
Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by gram-positive commensal vectors. Infect Immun (2002) 0.84
Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY. Antimicrob Agents Chemother (2012) 0.84
Development of ST-246® for Treatment of Poxvirus Infections. Viruses (2010) 0.84
Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys. PLoS One (2011) 0.83
A host cell membrane protein, golgin-97, is essential for poxvirus morphogenesis. Virology (2007) 0.83
Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods Mol Biol (2004) 0.82
Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol (2011) 0.82
Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches. J Comput Aided Mol Des (2007) 0.82
Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity. Virol J (2005) 0.82
A trans-Golgi network resident protein, golgin-97, accumulates in viral factories and incorporates into virions during poxvirus infection. J Virol (2006) 0.82
Sequence-independent acylation of the vaccinia virus A-type inclusion protein. Biochemistry (2004) 0.82
BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance. Biotechniques (2002) 0.82
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother (2012) 0.81
Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole. Bioorg Med Chem Lett (2012) 0.81
Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett (2012) 0.81
Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir Ther (2008) 0.81
Importance of disulphide bonds for vaccinia virus L1R protein function. Virol J (2005) 0.80
Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains. Virol J (2006) 0.80
Vaccinia virus A12L protein and its AG/A proteolysis play an important role in viral morphogenic transition. Virol J (2007) 0.79
Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism. Adv Drug Deliv Rev (2005) 0.79
Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother (2012) 0.79
Mass spectrometry analysis of synthetically myristoylated peptides. Eur J Mass Spectrom (Chichester, Eng) (2004) 0.79
Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmid. Can J Microbiol (2007) 0.78
Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus. Bioorg Med Chem Lett (2013) 0.78
Development of PLEX, a plasmid-based expression system for production of heterologous gene products by the gram-positive bacteria Streptococcus gordonii. Protein Expr Purif (2005) 0.77
Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine (2002) 0.77
Mutational analysis of the potential catalytic residues of the VV G1L metalloproteinase. Virol J (2006) 0.77
Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®. Antiviral Res (2012) 0.76
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother (2012) 0.75
Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection. PLoS One (2013) 0.75
Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV. Methods Mol Biol (2012) 0.75
Preparation of a large hydrophobic protein for mass spectrometry analysis: vaccina virus ATI protein. Anal Biochem (2003) 0.75
Antiviral options for biodefense. Curr Opin Virol (2013) 0.75